No Detail Found!

The comparison of efficacy between losartan and diltiazem as antiproteinuric agent in non-diabetic renal diseases

Author(s)
Salahuddin Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Malik Nadeem Azam Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Khalid Mehmood Raja Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Abdur Rehman Arshad Department of Nephrology, CMH, Peshawar, Pakistan
Faryal Riaz Khan Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Abdul Wahab Mir Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Taleah Tahir Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Batool Butt Department of Nephrology, Fauji Foundation Hospital, Rawalpindi, Pakistan
Wahaj Department of Nephrology, Abbottabad International Medical College, Abbottabad, Pakistan
Anum Khan Department of Nephrology, Pak Emirates Military Hospital, Rawalpindi, Pakistan
Abstract
Background: Multiple options have been tried to counter the proteinuria secondary to renal diseases. Clinicians and researchers are trying to find the best option for this purpose. Objective: To compare efficacy of Losartan and Diltiazem in management of proteinuria in nondiabetic renal diseases at a tertiary care hospital of Pakistan. It was a Quasi-experimental study, conducted at the Department of nephrology Pak Emirates Military Hospital Rawalpindi. Five months, November 2020 to March 2021. Methods: A total of 122 patients of non-diabetic renal diseases with significant proteinuria were included in the study. They were randomly divided into two groups via lottery method. Group I received losartan while group II received Diltiazem in standard dose for three months. After three months they underwent 24 hours' urinary protein levels and divided into complete, partial and non-responders to treatment. Age, gender, duration of illness and type of antiproteinuric treatment was correlated with response to treatment among the study population. Results: Out of 122 patients, 80 (65.6%) were males while 42 (34.4%) were females. Membranous nephropathy 20 (16.4%) was the commonest non-diabetic renal disease seen in our study participants. Thirty (24.5%) had complete remission after three months of treatment, 60 (49.2%) had partial response while 32 (26.3%) had no response to treatment. Chisquare test revealed that use of losartan had statistically significant relationship (p-value<0.001) with good response among the study participants. Conclusion: Membranous nephropathy leading to proteinuria was the commonest non-diabetic renal disease encountered in our setup. Around 2/3rd of our patients showed either complete or partial response to treatment and Losartan was superior to Diltiazem in achieving response in our study participants.
Publication Details
Page(s) 492-495
DOI DOI not available
Published Journal: Journal of Ayub Medical College, Volume: 33, Issue: 3, Year: 2021

Request the full text from PASTIC

Keywords
Proteinuria, Losartan, Diltiazem, Non-diabetic renal disease
0

Citations

0

Downloads

54

Views